KLG Stock +78.58% In 3 Months Since We Picked KLG Stock +78.58% In 3 Months Since We Picked Unlock All Top Buy Picks

Range Low Price High Price Comment
30 days $0.87 $1.65 Thursday, 25th Apr 2024 ADAP stock ended at $1.06. This is 1.85% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 5.69% from a day low at $1.04 to a day high of $1.10.
90 days $0.720 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Jan 07, 2022 $3.64 $3.67 $3.50 $3.51 494 000
Jan 06, 2022 $3.57 $3.65 $3.41 $3.61 755 000
Jan 05, 2022 $3.81 $3.89 $3.56 $3.58 661 500
Jan 04, 2022 $4.08 $4.12 $3.81 $3.84 605 844
Jan 03, 2022 $3.84 $4.10 $3.77 $4.06 499 390
Dec 31, 2021 $3.87 $3.95 $3.72 $3.75 922 569
Dec 30, 2021 $3.70 $3.93 $3.68 $3.87 676 107
Dec 29, 2021 $3.76 $3.81 $3.68 $3.70 356 276
Dec 28, 2021 $3.93 $4.06 $3.79 $3.79 515 034
Dec 27, 2021 $4.09 $4.10 $3.95 $3.95 319 108
Dec 23, 2021 $4.02 $4.17 $3.98 $4.11 914 146
Dec 22, 2021 $4.05 $4.11 $3.91 $4.00 889 935
Dec 21, 2021 $4.05 $4.11 $3.97 $4.01 586 599
Dec 20, 2021 $3.85 $4.14 $3.76 $4.06 1 016 224
Dec 17, 2021 $3.61 $3.99 $3.46 $3.90 1 918 938
Dec 16, 2021 $3.71 $3.72 $3.55 $3.61 768 398
Dec 15, 2021 $3.48 $3.69 $3.38 $3.68 932 403
Dec 14, 2021 $3.56 $3.61 $3.43 $3.50 990 014
Dec 13, 2021 $3.61 $3.70 $3.49 $3.61 606 246
Dec 10, 2021 $3.73 $3.89 $3.59 $3.62 1 145 989
Dec 09, 2021 $3.83 $3.90 $3.67 $3.69 527 560
Dec 08, 2021 $3.95 $3.95 $3.77 $3.83 1 201 134
Dec 07, 2021 $3.70 $4.00 $3.69 $3.89 962 837
Dec 06, 2021 $3.59 $3.63 $3.47 $3.59 1 122 751
Dec 03, 2021 $3.70 $3.70 $3.52 $3.58 1 021 248
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT